Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tweet chat

- PMLiVE

Novo Nordisk invests £115m in Oxford diabetes unit

But Danish pharma company admitted Brexit had made it a harder decision

- PMLiVE

J&J pondering future of diabetes device assets

Three diabetes care subsidiaries under review as firm forecasts measured 2017 sales

Novo signs personalised digital health deal in diabetes

Will work with Glooko on jointly-developed and branded solutions

Eli Lilly HQ

Lilly streamlines and culls leadership roles

Merges Europe and emerging markets interests and expands diabetes and oncology

- PMLiVE

M3 expands with acquisition of Vidal Group

Grows global operations to cover Europe and Latin America

Healthcare in the Digital Age

Healthcare is changing. By understanding the needs of the physicians, and using innovative channels to make meaningful connections, pharma can ensure it continues to enjoy a mutually beneficial relationship.

M3 (EU)

UK pharma continues to approach social media cautiously

Novartis UK becomes the latest in a trickle of firms to join Twitter

- PMLiVE

EU citizens are living longer, but not always in good health

Report finds huge inequalities between and within countries despite higher life expectancy

- PMLiVE

Sanofi launches ‘Highs & Lows’ diabetes awareness campaign

Highlights impact of emotional and psychological factors on effective self-management

Sanofi reception

FDA clears rival diabetes combos from Sanofi and Novo Nordisk

Xultophy set to launch in first half of 2017 while Soliqua is intended for January roll-out

- PMLiVE

Gilead’s hepatitis B virus treatment set for European approval

CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk

- PMLiVE

NHS marks its Twitter debut with story-sharing initiative

Three-month project will see a patient or staff member take over the new account

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links